1-20 of 104
Michael Lubbert
Close
Sort by
Journal Articles

Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial

Fabio Efficace, Michal Kicinski, Corneel Coens, Stefan Suciu, Walter J.F.M van der Velden, Richard Noppeney, Sylvain P Chantepie, Laimonas Griskevicius, Andreas Neubauer, Ernesta Audisio, Mario Luppi, Stephan Fuhrmann, Robin Foà, Martina Crysandt, Gianluca Gaidano, Radovan Vrhovac, Adriano Venditti, Eduardus F.M. Posthuma, Anna Candoni, Frédéric Baron, Olivier Legrand, Andrea Mengarelli, Paola Fazi, Marco Vignetti, Anne Giraut, Pierre W. Wijermans, Gerwin A Huls, Michael Lübbert
Journal: Blood
Blood blood.2023023625.
https://doi.org/10.1182/blood.2023023625
Published: 2024
Includes: Supplemental data
Journal Articles

Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation

David Alber, Christoph Rummelt, Tim Strüßmann, Andrés Rettig, Valeria Shlyakhto, Paul La Rosée, Martin Henkes, Elizaveta Bubnova, Tobias Ma, Johanna Thomas, Gabriele Ihorst, Claudia Wehr, Reinhard Marks, Heiko Becker, Justus Duyster, Ralph Wäsch, Jürgen Finke, Michael Lübbert
Journal: Blood
Blood (2023) 142 (Supplement 1): 7091.
https://doi.org/10.1182/blood-2023-187581
Published: 2023
Journal Articles

Treatment of a TP53 isogenic AML Cell Line Model with Decitabine and All Trans -Retinoic Acid (ATRA) Targets MYC for Antileukemic Activity in a p53-Independent Fashion

Usama-Ur Rehman, Steffen Boettcher, Michael Lübbert
Journal: Blood
Blood (2023) 142 (Supplement 1): 5745.
https://doi.org/10.1182/blood-2023-189202
Published: 2023
Journal Articles

Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- Trans Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

Michael Lübbert, Claudia Schmoor, Olga Grishina, Christoph Rummelt, Johanna Thomas, Michael Heuser, Konstanze Döhner, Hartmut Döhner, Heiko Becker, Ralph Wäsch
Journal: Blood
Blood (2023) 142 (Supplement 1): 1495.
https://doi.org/10.1182/blood-2023-181871
Published: 2023
Journal Articles

The Genomic Landscape and Its Clinical Implication in NPM1 -Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial

Sibylle Cocciardi, Nina Weiß, Maral Saadati, Sabrina Skambraks, Daniela Weber, Isabelle Schneider, Annika Meid, Sophia Aicher, Kathrin Bengesser-Kuhn, Andrea Corbacioglu, Verena I. Gaidzik, Frauke Theis, Walter Fiedler, Michael Kühn, Ulrich Germing, Karin T. Mayer, Michael Lübbert, Felicitas Thol, Michael Heuser, Arnold Ganser, Lars Bullinger, Axel Benner, Hartmut Döhner, Konstanze Döhner
Journal: Blood
Blood (2023) 142 (Supplement 1): 4311.
https://doi.org/10.1182/blood-2023-185566
Published: 2023
Journal Articles

Identification of Epigenetic Modifiers Essential for Growth and Survival of AML1/ETO-Positive Leukemia

Jesus Duque Afonso, Veratti Pia, Usama-Ur Rehman, Heike Herzog, Jan Mitschke, Gabriele Greve, Julian Eble, Bettina Berberich, Johanna Thomas, Milena Pantic, Miguel Waterhouse, Gaia Gentile, Olaf Heidenreich, Cornelius Miething, Michael Lübbert
Journal: Blood
Blood (2023) 142 (Supplement 1): 5687.
https://doi.org/10.1182/blood-2023-187372
Published: 2023
Journal Articles

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

Adriano Venditti, Michal Kicinski, Ernesta Audisio, Mario Luppi, Gianluca Gaidano, Robin Foà, Anna Candoni, Andrea Mengarelli, Attilio Olivieri, Annalisa Imovilli, Maurizio Musso, Paolo De Fabritiis, Eliana Zuffa, Nicola Cascavilla, Agostino Tafuri, Maria Ilaria Del Principe, Stefan Suciu, Anne Giraut, Stéphanie Antunes, Pierre W. Wijermans, Michael Lübbert, Geert A. Huls, Marco Vignetti, Francesco Buccisano
Journal: Blood
Blood (2023) 142 (Supplement 1): 2948.
https://doi.org/10.1182/blood-2023-184851
Published: 2023
Journal Articles

Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

Klaus Geissler, Zdenek Koristek, Teresa Bernal Del Castillo, Jan Novak, Gabriela Rodriguez Macias, Stephan Metzelder, Arpad Illes, Agnes Nagy, Jiří Mayer, Montserrat Arnan Sangerman, Mary-Margaret Keating, Jürgen Krauter, Monia Lunghi, Nicola Fracchiolla, Uwe Platzbecker, Valeria Santini, Danna Chan, Beloo Mirakhur, Yuri Sano, Aram Oganesian, Harold N. Keer, Michael Lübbert
Journal: Blood
Blood (2023) 142 (Supplement 1): 1538.
https://doi.org/10.1182/blood-2023-173092
Published: 2023
Journal Articles

Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All- Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Michael Lübbert, Claudia Schmoor, Tobias Berg, Michael Kruszewski, Marcus Matthias Schittenhelm, Katharina Götze, Caroline Pabst, Andrea Kündgen, Tobias Ma, Anna Frey, Kevin Moschallski, Usama-Ur Rehman, Johannes Jung, Justus Duyster, Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina
Journal: Blood
Blood (2022) 140 (Supplement 1): 9087–9088.
https://doi.org/10.1182/blood-2022-159471
Published: 2022
Journal Articles

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Michael W.M. Kühn, Thomas Schroeder, Karin Mayer, Michael Lübbert, Mohammad Wattad, Katharina Götze, Lars Fransecky, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Mark Ringhoffer, Richard Greil, Bernd Hertenstein, Jürgen Krauter, Uwe M. Martens, David Nachbaur, Maisun Abu Samra, Sigrid Machherndl-Spandl, Nadezda Basara, Claudia Leis, Anika Schrade, Silke Kapp-Schwoerer, Lars Bullinger, Felicitas R. Thol, Michael Heuser, Peter Paschka, Verena I. Gaidzik, Maral Saadati, Axel Benner, Richard F. Schlenk, Konstanze Döhner, Arnold Ganser
Journal: Blood
Blood (2022) 140 (Supplement 1): 2010–2013.
https://doi.org/10.1182/blood-2022-166084
Published: 2022
Journal Articles

All- Trans retinoic Acid Enhances the Antileukemic Activity of Decitabine and Venetoclax in Non-M3 AML Cells

Helena Bresser, Usama-Ur Rehman, Julia Schüler, Anne Rubarth, Tobias Ma, Gabriele Greve, Heiko Becker, Michael Lübbert
Journal: Blood
Blood (2022) 140 (Supplement 1): 11537–11539.
https://doi.org/10.1182/blood-2022-167743
Published: 2022
Journal Articles

Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients

Rabea Mecklenbrauck, Nora Borchert, Carolin Funke, Maximilian Brandes, Louisa-Kristin Dallmann, Piroska Klement, Walter Fiedler, Jürgen Krauter, Arne Trummer, Bernd Hertenstein, Andreas Voss, Michael Lübbert, Verena I. Gaidzik, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Felicitas R. Thol, Michael Heuser
Journal: Blood
Blood (2022) 140 (Supplement 1): 6254–6255.
https://doi.org/10.1182/blood-2022-162725
Published: 2022
Journal Articles

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Gerald Wulf, Helmut R. Salih, Michael Lübbert, Michael W.M. Kühn, Thomas Schroeder, Hans Salwender, Katharina S. Götze, Jörg Westermann, Lars Fransecky, Karin Mayer, Bernd Hertenstein, Mark Ringhoffer, Hans-Joachim Tischler, Sigrid Machherndl-Spandl, Anika Schrade, Peter Paschka, Verena I Gaidzik, Frauke Theis, Felicitas R Thol, Michael Heuser, Richard F. Schlenk, Lars Bullinger, Maral Saadati, Axel Benner, Konstanze Döhner, Arnold Ganser
Journal: Blood
Blood (2021) 138 (Supplement 1): 692.
https://doi.org/10.1182/blood-2021-147256
Published: 2021
Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Heiko Becker, Claudia Schmoor, Olga Grishina, Dietmar Pfeifer, Dennis Zimmer, Martina Crysandt, Edgar Jost, Felicitas Thol, Michael Heuser, Katharina S. Goetze, Richard F. Schlenk, Helmut R. Salih, Marcus M. Schittenhelm, Gerhard Heil, Carsten Schwaenen, Carsten Müller-Tidow, Wolfram Brugger, Andrea Kündgen, Ulrich Germing, Maike de Wit, Aristoteles Giagounidis, Sebastian Scholl, Andreas Neubauer, Jürgen Krauter, Gesine Bug, Annette M. May, Ralph Wäsch, Justus Duyster, Konstanze Döhner, Arnold Ganser, Hartmut Döhner, Björn Hackanson, Michael Lübbert
Journal: Blood
Blood (2021) 138 (Supplement 1): 2380.
https://doi.org/10.1182/blood-2021-146468
Published: 2021
Journal Articles

First-in-Human Study of WT1 Recombinant Protein Vaccination in Elderly Patients with AML in Remission: A Single-Center Experience

Stefanie Kreutmair, Dietmar Pfeifer, Miguel Waterhouse, Konstanze Döhner, Anna Frey, Justus Duyster, Anna Lena Illert, Michael Schmitt, Michael Lübbert
Journal: Blood
Blood (2021) 138 (Supplement 1): 1278.
https://doi.org/10.1182/blood-2021-150082
Published: 2021
Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Laura K. Schmalbrock, Anna Dolnik, Sibylle Cocciardi, Eric Sträng, Frauke Theis, Nikolaus Jahn, Ekaterina Panina, Tamara J. Blätte, Julia Herzig, Sabrina Skambraks, Frank G. Rücker, Verena I. Gaidzik, Peter Paschka, Walter Fiedler, Helmut R. Salih, Gerald Wulf, Thomas Schroeder, Michael Lübbert, Richard F. Schlenk, Felicitas Thol, Michael Heuser, Richard A. Larson, Arnold Ganser, Hendrik G. Stunnenberg, Saverio Minucci, Richard M. Stone, Clara D. Bloomfield, Hartmut Döhner, Konstanze Döhner, Lars Bullinger
Journal: Blood
Blood (2021) 137 (22): 3093–3104.
https://doi.org/10.1182/blood.2020007626
Published: 2021
Includes: Supplemental data
Journal Articles

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1 -mutated AML: results from the AMLSG 09-09 trial

Clinical Trials & Observations
Silke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, Verena I. Gaidzik, Peter Paschka, Jan Krönke, Frauke Theis, Frank G. Rücker, Maria-Veronica Teleanu, Ekaterina Panina, Nikolaus Jahn, Julia Herzig, Lena Kubanek, Anika Schrade, Gudrun Göhring, Walter Fiedler, Thomas Kindler, Thomas Schroeder, Karin T. Mayer, Michael Lübbert, Mohammed Wattad, Katharina S. Götze, Heinz A. Horst, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Martin Bentz, Jürgen Krauter, Lars Bullinger, Julia Krzykalla, Axel Benner, Richard F. Schlenk, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
Journal: Blood
Blood (2020) 136 (26): 3041–3050.
https://doi.org/10.1182/blood.2020005998
Published: 2020
Includes: Supplemental data
Journal Articles

Poor-Risk AML with Complex, Monosomal Karyotype: In Vivo Therapeutic Efficacy of Decitabine (DAC) in Patient-Derived Xenograft (PDX) Mouse Models

Gabriele Greve, PhD, Julia Schüler, DVM, Eva Oswald, PhD, Michael Lübbert
Journal: Blood
Blood (2019) 134 (Supplement_1): 2644.
https://doi.org/10.1182/blood-2019-126514
Published: 2019
Journal Articles

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

Frank G. Rücker, MD, Mridul Agrawal, MDMSc, Andrea Corbacioglu, PhD, Daniela Weber, Silke Kapp-Schwoerer, MD, Verena I. Gaidzik, MD, Nikolaus Jahn, MD, Thomas Schroeder, MD, Mohammad Wattad, MD, Michael Lübbert, Elisabeth Koller, MD, Thomas Kindler, MD, Katharina Götze, Mark Ringhoffer, MD, Jörg Westermann, MD, Walter Fiedler, MD, Heinz A. Horst, MD, Richard Greil, MD, Roland Schroers, Karin Mayer, MD, Thomas Heinicke, MD, Jürgen Krauter, MD, Richard F. Schlenk, MD, Felicitas Thol, MD, Michael Heuser, MD, Arnold Ganser, MD, Lars Bullinger, Peter Paschka, MD, Hartmut Döhner, MD, Konstanze Döhner
Journal: Blood
Blood (2019) 134 (Supplement_1): 2740.
https://doi.org/10.1182/blood-2019-125584
Published: 2019
Journal Articles

Decitabine-Induced Early Platelet Response, a Predictor of Favorable Outcome during Hypomethylating Treatment of MDS, Is Associated with In Vivo Megakaryocytic Differentiation

Julia Stomper, Annette M. May, Tina E. Joeckel, Peter Bronsert, Martin Werner, Michael Lübbert
Journal: Blood
Blood (2019) 134 (Supplement_1): 4265.
https://doi.org/10.1182/blood-2019-128141
Published: 2019